

Journal section: Oral Medicine and Pathology  
 Publication Types: Review

doi:10.4317/jced.53372  
<http://dx.doi.org/10.4317/jced.53372>

## Prophylaxis and antibiotic therapy in management protocols of patients treated with oral and intravenous bisphosphonates

Elena-Beatriz Bermúdez-Bejarano <sup>1</sup>, María-Ángeles Serrera-Figallo <sup>2</sup>, Aida Gutiérrez-Corrales <sup>1</sup>, Manuel-María Romero-Ruiz <sup>1</sup>, Raquel Castillo-de-Oyagüe <sup>3</sup>, José-Luis Gutiérrez-Pérez <sup>4</sup>, Daniel Torres-Lagares <sup>4</sup>

<sup>1</sup> Master's Degree in Oral Surgery. School of Dentistry. University of Seville

<sup>2</sup> Associate Professor. Integrated Dentistry and Patients with Special Diseases. School of Dentistry. University of Seville

<sup>3</sup> Professor of Prostheses. Department of Stomatology. School of Dentistry. Complutense University of Madrid

<sup>4</sup> Professor of Oral Surgery. School of Dentistry. University of Seville

### Correspondence:

Dental School – University of Seville  
 C/ Avicena s/n 41009  
 Sevilla, SPAIN  
[danieltl@us.es](mailto:danieltl@us.es)

Received: 16/07/2016  
 Accepted: 01/10/2016

Bermúdez-Bejarano EB, Serrera-Figallo MA, Gutiérrez-Corrales A, Romero-Ruiz MM, Castillo-de-Oyagüe R, Gutiérrez-Pérez JL, Torres-Lagares D. Prophylaxis and antibiotic therapy in management protocols of patients treated with oral and intravenous bisphosphonates. J Clin Exp Dent. 2017;9(1):e141-9.

<http://www.medicinaoral.com/odo/volumenes/v9i1/jcedv9i1p141.pdf>

Article Number: 53372 <http://www.medicinaoral.com/odo/indice.htm>  
 © Medicina Oral S. L. C.I.F. B 96689336 - eISSN: 1989-5488  
 eMail: [jced@jced.es](mailto:jced@jced.es)  
**Indexed in:**  
 Pubmed  
 Pubmed Central® (PMC)  
 Scopus  
 DOI® System

### Abstract

**Introduction:** Osteonecrosis of the jaw (MRONJ) linked to bisphosphonate treatment has specific characteristics that render its therapeutic management challenging for clinicians. Poor response to standard treatment makes it essential to take special precautions when treating this type of disease; therefore, antibiotic prophylaxis and/or antibiotic therapy have been proposed as effective and helpful tools in these situations.

**Objectives:** This article seeks to assess published evidence in order to evaluate the different protocols used for antibiotic prophylaxis and/or antibiotic therapy in the general context of patients treated with bisphosphonates.

**Material and Methods:** A literature review of the last 10 years was carried out in PubMed using the following keywords: “antibiotic prophylaxis and osteonecrosis,” “bisphosphonates AND osteonecrosis AND dental management,” “bisphosphonate AND osteonecrosis AND antibiotic prophylaxis AND oral surgery.” A total of 188 articles were obtained, of which 18 were ultimately selected.

**Results and Discussion:** In patients treated with oral and intravenous bisphosphonates without chemotherapy-associated osteonecrosis of the jaw, antibiotic prophylaxis prior to oral surgery is an important tool to avoid osteonecrosis and promote healing of the affected area. If the patient previously exhibited chemotherapy-associated osteonecrosis after tooth extraction, antibiotic prophylaxis is indicated to prevent recurrent osteonecrosis and promote healing of the extraction site. If chemotherapy-associated osteonecrosis is already present, antibiotic therapy is a vital part of conservative management to reduce the symptomatology of MRONJ and keep it from worsening. Finally, a lack of clinical data and randomized controlled trials makes it difficult to choose the most appropriate protocol for the various clinical situations studied.

**Key words:** Bisphosphonates, antibiotic prophylaxis, maxillary osteonecrosis, antibiotic treatment.

## Introduction

Antibiotic prophylaxis is used in dentistry to prevent infections in high-risk cases, such as during surgical procedures that enable pathogens to enter the body, or in patients whose general health characteristics or specific medical condition make them more susceptible to contracting new infections (1-5).

Consequently, prophylaxis is used to promote appropriate bioavailability of an antibiotic that can effectively tackle microorganisms and therefore prevent their proliferation and any subsequent infections. This concept is the opposite of antibiotic therapy, which is prescribed in cases of already established infection and is aimed at treating symptoms rather than preventing them (6).

Antibiotic prophylaxis and/or antibiotic therapy protocols have been established as an effective therapeutic tool in the prevention or conservative management of certain diseases. One such disease is chemotherapy-associated osteonecrosis of the jaw caused by bisphosphonates (or other drugs), described by Marx in 2003 (7) as an exposure of necrotic bone with more than eight weeks of evolution, associated with bisphosphonates and no prior radiation therapy. These lesions can progress and become infected or even suffer other complications, making them difficult to manage and with a wide range of therapies providing inconsistent results (8-10).

A distinction should be made between oral and intravenous routes of administration of bisphosphonates (11,12). Intravenous bisphosphonates are indicated for cancer patients (pamidronate and zoledronic acid); these are the most potent and are more likely to result in onset of MRONJ. They increase sevenfold the appearance of MRONJ after performing dental surgery, in comparison with oral bisphosphonates. In addition, it should be noted that the longer a treatment, the higher the risk of developing MRONJ, and larger doses also increase the risk of MRONJ. Intravenous bisphosphonates can remain in the blood for up to 10 years.

The onset of bisphosphonate-related MRONJ has also been correlated with different local factors (extractions, implant placement, periodontal disease, etc.) and systemic factors (endocrine disruptions, tobacco, alcohol, race, age, sex, etc.) (13,14).

In view of these risk factors, patient medical history, and the oral-systemic regions affected by bisphosphonates (including suppressed bone remodeling, deterioration of angiogenesis, toxicity of the soft tissues, modulatory dysfunction of the immune system, and delayed healing), there are many reasons to use antibiotic prophylaxis in patients treated with oral or intravenous bisphosphonates.

On the other hand, patients treated with oral or intravenous bisphosphonates who have already developed chemotherapy-associated osteonecrosis of the jaw may also benefit from antibiotic therapies to avoid potentially serious infection that can worsen symptoms; thus, anti-

biotic therapy can help improve overall clinical condition (15-17).

The present article seeks to identify the different published protocols of antibiotic prophylaxis and/or antibiotic therapy in patients treated with oral or intravenous bisphosphonates. To this end, a systematic review of the literature was carried out focusing on three clinical situations: a) patients treated with oral or intravenous bisphosphonates and without MRONJ who will undergo a dental extraction, b) patients treated with oral or intravenous bisphosphonates and with previous incidence of MRONJ who will undergo a dental extraction; and c) patients treated with oral or intravenous bisphosphonates and with MRONJ, as part of their conservative management.

## Material and Methods

A review of the literature published in PubMed over the last 10 years was carried out using the following keywords: “antibiotic prophylaxis and osteonecrosis,” “bisphosphonates AND osteonecrosis AND dental management,” “bisphosphonate AND osteonecrosis AND antibiotic prophylaxis AND oral surgery.” The results returned 29, 129, and 13 articles, respectively. The inclusion and exclusion criteria were then applied in order to fulfill the two proposed objectives.

The inclusion criteria for the first proposed objective (antibiotic prophylaxis protocols) were: academic publications written in English that involved reviews of the literature, clinical trials, case control studies, cohorts studies and case series centered on antibiotic prophylaxis (indicating the antibiotic used, doses, time, and dosage used for treatment) in patients treated with oral or intravenous bisphosphonates, with or without antecedents of developing chemotherapy-associated osteonecrosis of the jaw, who were undergoing oral surgery.

The inclusion criteria for the second proposed objective (antibiotic treatment guidelines) were: academic publications written in English that involved reviews of the literature, clinical trials, or case series that specify the type of antibiotic used, doses and length of treatment, and guidelines used for antibiotic therapy in patients treated with oral and intravenous bisphosphonates with MRONJ, as part of their conservative management (therefore, antibiotics are used as part of patient treatment).

The exclusion criteria for both proposed objectives were: articles that did not meet the eligibility requirements for both proposed objectives, articles unrelated to the research topic, articles that did not have an abstract or with an anonymous author, letters to the editor, and expert opinions.

The selection process was finished by manually searching through all the bibliographic references of the selected articles.

**Results**

The initial search in PubMed yielded 171 results, with an additional 17 articles identified during the manual search of the collected articles' bibliographic references. The flow chart seen in figure 1 details how the eligibility criteria were applied. A total of 18 articles were selected for final inclusion in the present study.

Results taken from the different articles can be seen in tables 1 to 3. Table 1 shows the antibiotic prophylaxis protocols applied to patients without previous MRONJ receiving treatment with oral bisphosphonates. The table also provides information on the antibiotic prophylaxis protocols used in patients without previous MRONJ receiving treatment with intravenous bisphosphonates. Table 2 is centered on antibiotic prophylaxis protocols in patients treated with oral or intravenous bisphosphonates who had previously had MRONJ. Lastly, Table 3, table 3 continue shows the antibiotic treatment protocols applied within a conservative management approach for patients with MRONJ receiving treatment with both oral and intravenous bisphosphonates.

When antibiotic prophylaxis is used in patients without previous MRONJ who are receiving treatment with oral bisphosphonates (Table 1), as well as in patients treated with intravenous bisphosphonates (Table 1), the most frequently used antibiotics are penicillin, amoxicillin, amoxicillin/clavulanic acid, metronidazole, and/or a combination thereof. Erythromycin, clindamycin, or even lincomycin are prescribed if the patient is allergic to penicillin or amoxicillin (15).

In the same way, the most widely used antibiotics for the treatment of MRONJ in patients taking oral bisphosphonates are penicillin, amoxicillin, amoxicillin/clavulanic acid, metronidazole, and/or a combination thereof. With regard to the length of prophylactic antibiotic treatment prior to and following tooth extraction, there is no uniform approach applied in all patients receiving treatment with oral or intravenous bisphosphonates. Despite this, most authors agree that post-extraction treatment regimens in patients receiving oral and intravenous bisphosphonates should be continued until the surgical site has completely healed.



Fig. 1. Flow Chart.

**Table 1.** Antibiotic prophylaxis in patients treated with oral and intravenous bisphosphonates without previous MRONJ and who will undergo an extraction.

Author/Year/ Type of study	Number of patients/ Average age	Number of and site of extractions	Oral Bisphosphonate: Treatment type, route of administration, time and number of patients	Causes for treatment with bisphosphonates and number of patients	Guidelines for antibiotic prophylaxis
INTRAORAL BISPSPHONATES					
Lodi <i>et al.</i> 2010 (14)  Prospective	23 patients  Average age: 68.2 years	38 extractions Mand: 23 Max: 5 Both: 2	Clodronate PO: 1  Duration of BP: 17.5 months	Multiple myeloma: 11 Mammary Ca.: 8 Solid tumors: 2 Severe osteoporosis: 2	Amox 1g/18h x 20d  3 days before and 17 days after extraction
Saia <i>et al.</i> 2010 (15)  Prospective	60 patients  Average age: 65 years	185 extractions Mand: 103 Max: 82	Risedronate PO: 2  Duration of BP: ND	Metabolic bone diseases: 16 Multiple myeloma: 44	Will be prescribed if: - there is no pain: 7 days after extraction - there is pain: 7 days before and after extraction  Guideline to follow:  Amox 1 g + Clavulanic acid 8h x 3d -Amox + Clavu ac. 1g/12h x 4d and Metro 500mg 8h x 4d  - Allergy: Linco 500mg 12h x 7d
INTRAVENOUS BISPSPHONATES					
Lodi <i>et al.</i> 2010 (14)  Prospective	23 patients  Average age: 68.2 years	38 extractions Mand: 23 Max: 5 Both: 2	Zoledronate IV: 20 Pamidronate IV: 1  Duration of BP: 17.5 months	Multiple myeloma: 11 Mammary Ca.: 8 Solid tumors: 2 Severe osteoporosis: 2	Amox 1g/18h x 20d  3 days before and 17 days after extraction
Saia <i>et al.</i> 2010 (15)  Prospective	60 patients  Average age: 65 years	185 extractions Mand: 103 Max: 82	Zoledronate IV: 38 Pamidronate IV: 15 Neridronate IV: 4  Duration of BP: ND	Metabolic bone diseases: 16 Multiple myeloma: 44	Prescribed if: - there is no pain: 7 days after extraction - there is pain: 7 days before and after extraction  Guideline to follow:  Amox 1g + Clavu ac 8h x 3d -Amox + Clavu ac. 1g/12h x 4d and Metro 500mg 8h x 4d  - Allergy: Linco 500mg 12h x 7d
Scoletta <i>et al.</i> 2011 (16)  Prospective	64 patients  Average age: 64.81 +/- 10.98 y	220 extractions  Mand: 113 Max: 107	Zoledronate IV: 57 Pamidronate IV: 2 Zoled IV/Pam IV: 5  Duration of BP: 19.59 +/-18.95 months	Mammary Ca.: 32 Multiple myeloma: 21 Osteoporosis: 2 Prostate Ca.: 4 Other diseases: 3 Other cancers: 3	Amox/ Clavulanate potassium 1g 8h x 6d  Allergy: Erythromycin 600mg 8h x 6d  1 day before and 5 days after extraction
Ferlito <i>et al.</i> 2011 (17)  Case series	43 patients  Average age: 56.4 y	102 extractions Mand: 43 Max: 59	Zoledronate IV  Duration of BP: 16.2 +/- 3.2 months	Multiple myeloma: 28 Mammary Ca.: 8 Prostate Ca.: 5 Lung Ca.: 2	Prophylaxis: Amox + Clavu ac. 1g/12 h  2 days before and 5 days after extraction
Kato <i>et al.</i> 2013 (19)  Retrospective	20 patients  Average age: 62.2 y	62 extractions Mand: 36 Max: 26	Zoledronate IV: 14 Pamidronate IV: 6 Zoled IV/Pam IV: 1  Duration of BP: 1- 85 months	Mammary Ca.: 11 Multiple myeloma: 5 Prostate Ca.: 3 Non-Hodgkin's lymphoma 1	Amox -Amox + Metro - Clindamycin  1 day before and 9 days after extraction

Abbreviations: BP: Bisphosphonates; IV: Intravenous; PO: Oral; IM: Intramuscular; MRONJ: Osteonecrosis of the jaw; ND: Not documented; Ca.: Cancer; Metro: Metronidazole; Amox: Amoxicillin; Amox/Clavu ac.: Amoxicillin / Clavulanic Acid; Linco: Lincomycin; Erythro: Erythromycin; Clinda: Clindamycin; Peni: Penicillin.

**Table 2.** Antibiotic prophylaxis in patients treated with oral (0 articles) or intravenous bisphosphonates without previous MRONJ and who will undergo an extraction.

Author/Year/ Type of study	Number of patients/ Average age	Number of and site of extractions	Treatment type, route of administration, time and number of patients	Causes for treatment with bisphosphonates and number of patients	Guidelines for antibiotic prophylaxis
INTRAVENOUS BIPHOSPHONATES					
Vescovi <i>et al.</i> 2015 (20)  Prospective	36 patients  Average age: 68.5 y	82 extractions  Mand: 51 Max: 31	Zoledronate IV  Duration of BP: 9-24 months	Multiple myeloma: 11 Osteoporosis: 7 Other cancers: 18	Extraction prophylaxis: Amox 2g/d  Management of MRONJ: Same treatment as before and Metro 1g/d  3 days before and 2 weeks after extraction

Abbreviations: BP Bisphosphonates; IV: Intravenous; PO: Oral; IM: Intramuscular; MRONJ: Osteonecrosis of the jaw; ND: Not documented; Ca.: Cancer; Metro: Metronidazole; Amox: Amoxicillin; Amox/Clavu ac.: Amoxicillin / Clavulanic Acid; Linco: Lincomycin; Erythro: Erythromycin; Clinda: Clindamycin; Peni: Penicillin.

**Discussion**

Antibiotic prophylaxis can be beneficial in avoiding the onset of MRONJ in patients who are set to undergo oral surgery (extraction) and are currently being treated with oral and intravenous bisphosphonates. If MRONJ has already developed and is under control, antibiotic treatment prophylaxis can prevent its recurrence. Moreover, antibiotic prophylaxis can help reduce the symptoms of osteonecrosis of the jaw, aiding in a conservative management regimen. However, despite the many studies found in the literature, there is no consensus on which is the most used antibiotic and its dosage (17). The latest consensus of the American Association of Oral and Maxillofacial Surgeons (AAOMS) (18) refers to the use of antibiotics in the systemic management of such patients in Stage 0 (“Systemic management, including use of pain medication and antibiotics”). Given that the same article identifies this stage as a moment in which there is no clinical evidence of MRONJ, this kind of situation would be the first group of study of our article. Aside from this indication, consensus doesn’t detail the most useful antibiotics or that they should be used. For this reason, clinical experience collected in this review could be useful (18). Antibiotics used in patients without previous MRONJ who are receiving treatment with oral bisphosphonates, as well as in patients treated with intravenous bisphosphonates (Table 1), have already been exposed in the Results section. With regard to the length of prophylactic antibiotic treatment prior to and following tooth extraction, there is no uniform approach applied in all patients receiving treatment with oral or intravenous bisphosphonates. Some articles indicate that antibiotics should be prescribed three (14) or seven (15) days before tooth extraction in patients treated with oral bisphosphonates.

Similarly, post-extraction recommendations vary, with articles suggesting that antibiotic prophylaxis be administered anywhere from seven (15) to seventeen days (14) post-intervention. For patients receiving treatment with intravenous bisphosphonates, the articles’ recommendations for when to begin pre-extraction prescription of antibiotics range from one, (16,19) two, (17) or three days before (14) to seven days before extraction (15). Post-extraction antibiotic treatment is recommended to be started five, (16-18) seven, (15) nine, (19) or seventeen days (14) after the procedure. Despite this, most authors agree that post-extraction treatment regimens in patients receiving oral and intravenous bisphosphonates should be continued until the surgical site has completely healed. For the above reasons, the total length of treatment time can vary greatly. Patients treated with oral bisphosphonates can receive prophylaxis for anywhere from seven (15) to twenty days (14). In patients treated with intravenous bisphosphonates, treatment time can range from six (16) or seven (15,17) to twenty (14) days. Regarding the use of antibiotics for the treatment of MRONJ, the consensus of the AAOMS (18) identifies as necessary from Stage 2, indicating that the isolated microorganisms are often sensitive to penicillin. Although it indicates a wide variety of antibiotics used to treat MRONJ not identify dose or temporal patterns, which if addressed in this paper, can help fill that consensus. No articles were found on administering antibiotic prophylaxis in patients receiving oral treatment with bisphosphonates who had also suffered previous osteonecrosis of the jaw and were set to undergo an extraction in the near future. Regarding patients undergoing intravenous bisphosphonate treatment, only one article was found, in which the authors prescribe amoxicillin before

**Table 3.** Antibiotic therapy as a conservative management in patients treated with oral and intravenous bisphosphonates with MRONJ.

Author/Year/ Type of study	Number of patients/ Average age	Number of and site of extractions	Treatment type, route of administration, time and number of patients	Causes for treatment with bisphosphonates and number of patients	Antibiotic treatment
<b>ORAL BISPSPHONATES</b>					
Alons <i>et al.</i> 2009 (21) Retrospective	7 patients Average age: 66.9 y	7 MRONJ Location: Mand: 5/ Max: 1/ Both: 1 Stages: ND	Clodronate PO: 1 Combination of BP: 3  Duration of BP: 48 months	Multiple myeloma: 1 Mammary Ca.: 2 Osteoporosis: 1 Combination of diseases: 1	6 million U Penicillin G + 1500mg Metro IV 1x a day x 1 week  Fenticillin PO 1 x d + 1500mg Metro PO 1x a day x 2 weeks  Allergy: 1800mg Clinda IV 1x a day x 1 week + 1800mg Clinda PO 1x a day x 3 weeks
Stanton <i>et al.</i> 2009 (22) Retrospective	33 patients Average age: 64.5 y	33 MRONJ Location: Mand: 25/ Max: 8/ Both: 2 Stages: ND	Alendronate PO: 3 Combination of BP: 4  Duration of BP: ND	Mammary Ca.: 18 Multiple myeloma: 5 Prostate Ca.: 3 Non-Hodgkin's lymphoma 1 Osteoporosis: 4 Combination of diseases: 2	Before and after surgical intervention: Levo + Metro 4 weeks until complete healing  Allergy to Levo: Metro or Peni
Ferlito <i>et al.</i> 2012 (23) Case series	94 patients Average age: 66 y	94 MRONJ Location: ND Stages: Stage I: 8/ Stage II: 86	94 MRONJ Location: ND Stages: Stage I: 8/ Stage II: 86	ND	Pre-surgical intervention: Stage I: Piperacillin/Tazobactam IM 2g/ 12h x 5d Stage II: Imipenem/Cilastatin IV 500mg 12h x 2d  Post-surgical intervention: Stage I: Piperacillin/Tazobactam IM 2g/ 12h x 7d Stage II: Stage II: Imipenem/Cilastatin IV 500mg 12h x 3d
Williamson <i>et al.</i> 2010 (24) Prospective	40 patients Average age: 64 y	40 MRONJ Location: Mand: 25/ Both: 15 Stages: Refractory MRONJ	Oral Bisphosphonates: 16  Duration of BP: ND	Multiple myeloma: 4 Metastasis of prostate ca.: 8 Mammary Ca.: 1 Osteoporosis: 15 Paget's disease: 2	Before surgical intervention: Amox 1g After surgical intervention: Amox 500mg 6h x 2weeks  Allergy: Clinda 600mg before and after 450mg 6h x 2 weeks
Eckardt <i>et al.</i> 2011 (25) Case series	142 patients Average age: 62 y	142 MRONJ Location: Mand: 82/ Max: 39/ Both: 21 Stages: ND	Ibandronate PO: 20 Alendronate PO: 12 Etidronate PO: 1 Risedronate PO: 3 Clodronate PO: 1 Combination of BP: 2 Duration of BP: 37.1 months	Mammary Ca.: 51 Prostate Ca.: 20 Plasmacytoma: 34 Renal Ca.: 8 Lung Ca.: 8 Other cancers: 9 Other diseases: 2	Pre- and post-surgical intervention: Peni and for allergies: Clinda
Vescovi <i>et al.</i> 2012 (26) Case series	151 patients Average age: 66.6 y	139 MRONJ Location: Mand: 95/ Max: 42/ Both: 14 Stages: Stage I: 24/ Stage II: 102/ Stage III: 25	Alendronate PO: 16 Combination of BP: 29  Duration of BP: 48.2 months	Multiple myeloma: 56 Bone metastasis: 65 Osteoporosis: 30	Amox PO: 1g 8h x 2 weeks Metro PO: 250mg 12h/ x 2 weeks  3 days before and 10 days after surgical intervention
Eckert <i>et al.</i> 2007 (27) Case series	24 patients Average age: 67 y	24 MRONJ Location: Mand: 16/ Max: 8  Stages: ND	Alendronate PO: 3 Ibandronate PO: 1 Combination of BP: 9  Duration of BP: 4-84 months	Mammary Ca.: 9 Multiple myeloma: 7 Prostate Ca.: 5 Lung Ca.: 1 Osteoporosis: 2	Antibiotic treatment:  Amox + Clavu ac. 1 week
Junquera <i>et al.</i> 2009 (28) Case series	21 patients Average age: 65.1 y	21 MRONJ Location: Mand: 17/ Max: 4 Stages: Stage I: 7/ Stage II: 9/ Stage III: 5	Alendronate PO: 1  Duration of BP: 11.2 months	Multiple myeloma: 5 Bone metastasis of Mammary Ca.: 13 Rheumatoid arthritis 1 Prostate Ca.: 2	Amox 2-4g per day + Clavu ac. 125-250mg per day x 2 weeks

**Table 3 (continue).** Antibiotic therapy as a conservative management in patients treated with oral and intravenous bisphosphonates with MRONJ.

Epstein <i>et al.</i> 2010 (29) Case series	6 patients Average age: 75 y	6 MRONJ Location: ND Stages: ND	Ibandronate PO: 1 Alendronate PO: 1  Duration of BP: ND	Cancer patients: 4 Osteoporosis: 2	Pentoxifylline and alpha-Tocopherol
INTRAVENOUS BISPHOSPHONATES					
Eckert <i>et al.</i> 2007 (27) Case series	24 patients Average age: 67 y	24 MRONJ Location: Mand: 16/ Max: 8  Stages: ND	Zoledronic acid IV: 9 Pamidronate IV: 2 Combination of BP: 9  Duration of BP: 4-84 months	Mammary Ca.: 9 Multiple myeloma: 7 Prostate Ca.: 5 Lung Ca.: 1 Osteoporosis: 2	Antibiotic treatment:  Amox + Clavu ac. 1 week
Van De Wyngert <i>et al.</i> 2008 (30) Case report	33 patients Average age: 58 y	33 MRONJ Location: Mand: 17/ Max: 11/ Both: 5 Stages: Stage I: 9/ Stage II: 21/ Stage III: 3	Zoledronic acid IV: 21 Pamidronate IV: 6 Combination of BP: 27  Duration of BP: 27 months	Multiple myeloma: 9 Mammary Ca.: 19 Prostate Ca.: 3 Renal cell Ca.: 11	Amox + Clavu ac. 875/125mg Allergy: Clinda 300mg 8h x 10d Maintenance therapy: Doxi 100mg 1x a day x 3 weeks until complete healing
Alons <i>et al.</i> 2009 (21) Retrospective	7 patients Average age: 66.9 y	7 MRONJ Location: Mand: 5/ Max: 1/ Both: 1 Stages: ND	Pamidronate IV: 3 Combination of BP: 3  Duration of BP: 48 months	Multiple myeloma: 1 Mammary Ca.: 2 Osteoporosis: 1 Combination of diseases: 1	6 million U Penicillin G + 1500mg Metro 1x a day x 1 week IV  Fenticillin 1x d + 1500mg PO + Metro 1x a day x 2 weeks PO  Allergy: 1800mg Clinda 1x a day x 1 week IV + 1800mg Clinda 1x a day x 3 weeks PO
Saussez <i>et al.</i> 2009 (31) Retrospective	34 patients Average age: 62 y	34 MRONJ Location: Mand: 18/ Max: 8/ Both: 7 Stages: Stage I: 7/ Stage II: 22/ Stage III: 5	Zoledronic acid IV: 21 Pamidronate IV: 3 Unknown: 1 Combination of BP: 9  Duration of BP: ND	Bone metastasis of mammary Ca.: 16 Prostate Ca.: 4 Multiple myeloma: 6  Other cancers: 4 Osteoporosis: 4	Amoxicillin or Amox/Clavu acid Allergy: Clinda or Doxi
Junquera <i>et al.</i> 2009 (28) Case series	21 patients Average age: 65.1 y	21 MRONJ Location: Mand: 17/ Max: 4 Stages: Stage I: 7/ Stage II: 9/ Stage III: 5	Zoledronic acid IV: 19 Pamidronate IV: 1  Duration of BP: 11.2 months	Multiple myeloma: 5 Bone metastasis of mammary Ca.: 13 Rheumatoid arthritis: 1 Prostate Ca.: 2	Amox 2-4g per day + Clavu ac. 125-250mg a day x 2 weeks
Stanton <i>et al.</i> 2009 (22) Retrospective	33 patients Average age: 64.5 y	33 MRONJ Location: Mand: 25/ Max: 8/ Both: 2 Stages: ND	Zoledronic acid IV: 26 Combination of BP: 4  Duration of BP: ND	Mammary Ca.: 18 Multiple myeloma: 5 Prostate Ca.: 3 Non-Hodgkin's lymphoma: 1 Osteoporosis: 4 Combination of diseases: 2	Before and after surgical intervention: Levo + Metro 4 weeks until complete healing  Allergy to Levo: Metro or Peni
Epstein <i>et al.</i> 2010 (29) Case series	6 patients Average age: 75 y	6 MRONJ Location: ND Stages: ND	Zoledronic acid IV: 2 Pamidronate IV: 2  Duration of BP: ND	Cancer patients: 4 Osteoporosis: 2	Pentoxifylline and alpha-Tocopherol
Williamson <i>et al.</i> 2010 (24) Prospective	40 patients Average age: 64 y	40 MRONJ Location: Mand: 25/ Both: 15 Stages: Refractory MRONJ	Bisphosphonates IV: 24  Duration of BP: ND	Multiple myeloma: 4 Metastasis of prostate Ca.: 8 Mammary Ca.: 1 Osteoporosis: 15 Paget's disease: 2	Before surgical intervention: Amox 1g After surgical intervention: Amox 500mg 4x a day x 2 weeks  Allergy: Clinda 600mg before and after 450mg 4 a d x 2 weeks
Eckardt <i>et al.</i> 2011 (25) Case series	142 patients Average age: 62 y	142 MRONJ Location: Mand: 82/ Max: 39/ Both: 21 Stages: ND	Zoledronic acid IV: 82 Pamidronate IV: 21 Combination of BP: 2  Duration of BP: 37.1 months	Mammary Ca.: 51 Prostate Ca.: 20 Plasmacytoma: 34 Renal Ca.: 14 Lung Ca.: 8 Other cancers: 9 Other diseases: 2	Pre- and post-surgical intervention: Peni and for allergies: Clinda

the extraction and add metronidazole after the procedure (20). The pharmaceutical treatment began three days prior to the procedure and was continued for two weeks afterwards (18 days in total) (20). Long-term antibiotic treatment appears to yield better re-

sults in regard to promoting proper healing of the alveolar sockets (17,20) and avoiding the onset of MRONJ. The most widely used antibiotics for the treatment of MRONJ in patients taking oral bisphosphonates are similar to the used in the first group of clinical situations:

**Table 3 (continue-1).** Antibiotic therapy as a conservative management in patients treated with oral and intravenous bisphosphonates with MRONJ.

Hoefert <i>et al.</i> 2011(32) Retrospective	46 patients Average age: 66-83 y	47 MRONJ Location: Mand: 33 / Max: 9/ Both: 5 Stages: Stage I: 10/ Stage II: 37	Zoledronic acid IV: 20 Pamidronate IV: 5 Ibandronate IV: 5 Combination of BP: 17  Duration of BP: ND	Multiple myeloma: 11 Metastasis of lung Ca.: 3 Prostate Ca.: 4 Mammary Ca.: 28 Colon Ca.: 2 Renal Ca.: 3 Unknown: 6	Two groups and different guidelines:  -Group A-ST: Oral: Pre-surgical intervention 1-8d  -Group B-LT: Oral: Pre-intervention 23-54d  Post-surgical intervention for both groups: Oral: 10-12d / IV: 7 d  ABX used in both groups: Amox, Levo, Clinda, Cefaclor, Cefuroxime, Cipro, Cefacidin, Moxiflox, Doxi and Metro
Ferlito <i>et al.</i> 2012 (23) Case series	94 patients Average age: 66 y	94 MRONJ Location: ND Stages: Stage I: 8/ Stage II: 86	Zoledronic acid IV: 72 Clodronate IM: 1 Ibandronate IV: 1 Neridronate IV: 4  Duration of BP: 24 months	ND	Pre-surgical intervention: Stage I: Piperacillin/Tazobactam 2g/ 12h x 5d IM Stage II: Imipenem/Cilastatin 500mg 12h x 2d IV  Post- surgical intervention: Stage I: Piperacillin/Tazobactam 2g/ 12h x 7d IM Stage II: Stage II: Imipenem/Cilastatin IV: 500mg 12h x 3d
Vescovi <i>et al.</i> 2012 (26) Case series	151 patients Average age: 66.6 y	139 MRONJ Location: Mand: 95/ Max: 42/ Both: 14 Stages: Stage I: 24/ Stage II: 102/ Stage III: 25	Zoledronic acid IV: 87 Pamidronate IV: 2  Combination of BP: 29  Duration of BP: 48.2 months	Multiple myeloma: 56 Bone metastasis: 65 Osteoporosis: 30	Amox PO: 1g 3x a d x 2 weeks Metro PO: 250mg 2x a d x 2 weeks  3 days before and 10 days after surgical intervention

Abbreviations: BP: Bisphosphonates; IV: Intravenous; PO: Oral; IM: Intramuscular; MRONJ: Osteonecrosis of the jaw; ND: Not documented; Ca.: Cancer; Metro: Metronidazole; Amox: Amoxicillin, Amox/Clavu ac.: Amoxicillin / Clavulanic acid, Linco: Lincomycin, Erythro: Erythromycin, Clinda: Clindamycin, Peni: Penicillin; Levo: Levofloxacin; Doxi: Doxicilin; A-ST: Short-term preoperative antibiotic regime; B-LT: Long-term preoperative antibiotic regime.

penicillin, amoxicillin, amoxicillin/clavulanic acid, metronidazole, and/or a combination thereof. There are also studies that prescribed penicillin G + IV metronidazole, (21) levofloxacin + metronidazole, (22) piperacillin + tazobactam, or imipenem + cilastatin (23). If the patient is allergic to penicillin or amoxicillin, clindamycin is usually prescribed instead (21,24-26,30-32).

There is no consensus on total treatment time. Authors' recommendations for conservative management of MRONJ using antibiotics include one week, (27) ten days, (26) fifteen days (24,26,28,29), or three or four weeks, until the healing process is complete (21,22). Most of the consulted studies agree that antibiotic treatment should be long-term. This is because depending on the severity of MRONJ, conservative treatment may be accompanied by surgical treatments with varying levels of invasiveness. Consequently, antibiotic therapy is often continued long-term until the clinical remission of signs and symptoms linked to MRONJ or its surgical treatment.

In patients treated with intravenous bisphosphonates, the most commonly used antibiotics are penicillin, amoxicillin, amoxicillin/clavulanic acid, metronidazole, and/or a combination thereof. Some studies also prescribed penicillin G + IV metronidazole, (21) levofloxacin + me-

tronicidazole, (22) piperacillin + tazobactam, or imipenem + cilastatin (23). If the patient is allergic to penicillin or amoxicillin, clindamycin is usually prescribed instead (21,24-26,30-32).

No consensus exists on total treatment times, with the approach being similar to treatments described for patients undergoing treatment with oral bisphosphonates.

In any case, it is always best to carry out antibiogram before prescribing any antibiotics; (12) however, broad spectrum antibiotics can be used in cases where MRONJ must be treated as soon as possible.

Sparse clinical data and a lack of randomized controlled trials make it impossible to definitively identify the most appropriate protocol for each of the different clinical situations studied (33,34).

In conclusion, it is clear that in patients being treated with oral and intravenous bisphosphonates who have not had prior chemotherapy-associated osteonecrosis of the jaw, the use of antibiotic prophylaxis prior to oral surgery is an important tool in avoiding osteonecrosis and in promoting proper healing of the affected area. If a patient previously had chemotherapy-associated osteonecrosis after a tooth extraction, antibiotic prophylaxis will be indicated to prevent the recurrence of osteonecrosis and to promote healing of the extraction site. If



chemotherapy-associated osteonecrosis is already present, antibiotic therapy is a vital part of conservative management to reduce the symptomatology of MRONJ and keep it from worsening.

## References

- French Health Products Safety Agency (Afsaps). Prescribing antibiotics in odontology and stomatology. Recommendations by the French Health Products Safety Agency. *Fundam Clin Pharmacol*. 2003;17:725-9.
- Peterson LJ. Antibiotic prophylaxis against wound infections in oral and maxillofacial surgery. *J Oral Maxillofac Surg*. 1990;48:617-20.
- Tong DC, Rothwell BR. Antibiotic prophylaxis in dentistry: a review and practice recommendations. *J Am Dent Assoc*. 2000;131:366-74.
- Carmona IT, Diz Dios P, Scully C. An update on the controversies in bacterial endocarditis of oral origin. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod*. 2002;93:660-70.
- Shrout MK, Scarbrough F, Powell BJ. Dental care and the prosthetic joint patient: a survey of orthopedic surgeons and general dentists. *J Am Dent Assoc*. 1994;125:429-36.
- Gutiérrez JL, Bagán JV, Bascones A, Llamas R, Llana J, Morales A, et al. Consensus document on the use of antibiotic prophylaxis in dental surgery and procedures. *Med Oral Patol Oral Cir Bucal*. 2006;11:E188-205.
- Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. *J Oral Maxillofac Surg*. 2003;61:1115-7.
- Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. *J Oral Maxillofac Surg*. 2005;63:1567-75.
- Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. *J Oral Maxillofac Surg*. 2004;62:527-34.
- Leizaola-Cardesa IO, Aguilar-Salvaterra A, Gonzalez-Jaranay M, Moreu G, Sala-Romero MJ, Gómez-Moreno G. Bisphosphonates, vitamin D, parathyroid hormone, and osteonecrosis of the jaw. Could there be a missing link? *Med Oral Patol Oral Cir Bucal*. 2016;21:e236-40.
- Ponte Fernández N, Estefanía Fresco R, Aguirre Urizar JM. Bisphosphonates and oral pathology I. General and preventive aspects. *Med Oral Patol Oral Cir Bucal*. 2006;11:E396-400.
- Bagán J, Blade J, Cozar JM, Constela M, García Sanz R, Gómez Veiga F, et al. Recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw (ONJ) in cancer patients treated with bisphosphonates. *Med Oral Patol Oral Cir Bucal*. 2007;12:E336-40.
- Campisi G, Di Fede O, Musciotto A, Lo Casto A, Lo Muzio L, Fulfaro F, et al. Bisphosphonate-related osteonecrosis of the jaw (BR-MRONJ): run dental management designs and issues in diagnosis. *Ann Oncol*. 2007;18 Suppl 6:vii168-72.
- Lodi G, Sardella A, Salis A, Demarosi F, Tarozzi M, Carrassi A. Tooth extraction in patients taking intravenous bisphosphonates: a preventive protocol and case series. *J Oral Maxillofac Surg*. 2010;68:107-10.
- Saia G, Blandamura S, Bettini G, Tronchet A, Totola A, Bedogni G, et al. Occurrence of bisphosphonate-related osteonecrosis of the jaw after surgical tooth extraction. *J Oral Maxillofac Surg*. 2010;68:797-804.
- Scoletta M, Arduino PG, Pol R, Arata V, Silvestri S, Chiecchio A, et al. Initial experience on the outcome of teeth extractions in intravenous bisphosphonate-treated patients: a cautionary report. *J Oral Maxillofac Surg*. 2011;69:456-62.
- Ferlito S, Puzzo S, Liardo C. Preventive protocol for tooth extractions in patients treated with zoledronate: a case series. *J Oral Maxillofac Surg*. 2011;69:e1-4.
- Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, et al. American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. *J Oral Maxillofac Surg*. 2014;72(10):1938-56.
- Mozzati M, Gallesio G, Arata V, Pol R, Scoletta M. Platelet-rich therapies in the treatment of intravenous bisphosphonate-related osteonecrosis of the jaw: a report of 32 cases. *Oral Oncol*. 2012;48:469-74.
- Kato GF, Lopes RN, Jaguar GC, Silva AP, Alves FA. Evaluation of socket healing in patients undergoing bisphosphonate therapy: experience of a single Institution. *Med Oral Patol Oral Cir Bucal*. 2013;18:e650-6.
- Vescovi P, Giovannacci I, Merigo E, Meleti M, Manfredi M, Fornaini C, et al. Tooth extractions in high-risk patients under bisphosphonate therapy and previously affected with osteonecrosis of the jaws: surgical protocol supported by low-level laser therapy. *J Craniofac Surg*. 2015;26:696-9.
- Alons K, Kuijpers SC, de Jong E, van Merkesteyn JP. Treating low- and medium-potency bisphosphonate-related osteonecrosis of the jaws with a protocol for the treatment of chronic suppurative osteomyelitis: report of 7 cases. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod*. 2009;107:e1-7.
- Stanton DC, Balasanian E. Outcome of surgical management of bisphosphonate-related osteonecrosis of the jaws: review of 33 surgical cases. *J Oral Maxillofac Surg*. 2009;67:943-50.
- Ferlito S, Puzzo S, Palermo F, Verzi P. Treatment of bisphosphonate-related osteonecrosis of the jaws: presentation of a protocol and an observational longitudinal study of an Italian series of cases. *Br J Oral Maxillofac Surg*. 2012;50:425-9.
- Williamson RA. Surgical management of bisphosphonate induced osteonecrosis of the jaws. *Int J Oral Maxillofac Surg*. 2010;39:251-5.
- Eckardt AM, Lemound J, Lindhorst D, Rana M, Gellrich NC. Surgical management of bisphosphonate-related osteonecrosis of the jaw in oncologic patients: a challenging problem. *Anticancer Res*. 2011;31:2313-8.
- Vescovi P, Merigo E, Meleti M, Manfredi M, Guidotti R, Nammour S. Bisphosphonates-related osteonecrosis of the jaws: a concise review of the literature and a report of a single-centre experience with 151 patients. *J Oral Pathol Med*. 2012;41:214-21.
- Eckert AW, Maurer P, Meyer L, Kriwalsky MS, Rohrberg R, Schneider D, et al. Bisphosphonate-related jaw necrosis-severe complication in maxillofacial surgery. *Cancer Treat Rev*. 2007;33:58-63.
- Junquera L, Gallego L, Cuesta P, Pelaz A, de Vicente JC. Clinical experiences with bisphosphonate-associated osteonecrosis of the jaws: analysis of 21 cases. *Am J Otolaryngol*. 2009;30:390-5.
- Epstein MS, Wicknick FW, Epstein JB, Berenson JR, Gorsky M. Management of bisphosphonate-associated osteonecrosis: pentoxifylline and tocopherol in addition to antimicrobial therapy. An initial case series. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod*. 2010;110:593-6.
- Van den Wyngaert T, Claeys T, Huizing MT, Vermorken JB, Fosson E. Initial experience with conservative treatment in cancer patients with osteonecrosis of the jaw (ONJ) and predictors of outcome. *Ann Oncol*. 2009;20:331-6.
- Saussez S, Javadian R, Hupin C, Magremanne M, Chantratin G, Loeb I, et al. Bisphosphonate-related osteonecrosis of the jaw and its associated risk factors: a Belgian case series. *Laryngoscope*. 2009;119:323-9.
- Hoefert S, Eufinger H. Relevance of a prolonged preoperative antibiotic regime in the treatment of bisphosphonate-related osteonecrosis of the jaw. *J Oral Maxillofac Surg*. 2011;69:362-80.
- Vidal-Real C, Pérez-Sayáns M, Suárez-Peñaranda JM, Gándara-Rey JM, García-García A. Osteonecrosis of the jaws in 194 patients who have undergone intravenous bisphosphonate therapy in Spain. *Med Oral Patol Oral Cir Bucal*. 2015;20:e267-72.
- Gavaldá C, Bagán JV. Concept, diagnosis and classification of bisphosphonate-associated osteonecrosis of the jaws. A review of the literature. *Med Oral Patol Oral Cir Bucal*. 2016;21:e260-70.

## Conflict of Interest

The authors have declared that no conflict of interest exist.